Dr C. Michael Gibson (Beth Israel Deaconess Medical Center, Boston, MA, US) discusses Rivaroxaban 2.5 mg BID combined with DAPT for the prevention of death/MI/stroke - a patient level data meta-analysis of the ATLAS-ACS-2 TIMI-51 and the COMMANDER HF trials
Filmed on site at CRT 2019 by Radcliffe Cardiology
1. Why did you conduct this analysis?
2. How was data collected and analysed?
3. What were your findings?
4. How does this compliment existing data and what are the implications for practice?